eng Oriental Scientific Publishing Company Biomedical and Pharmacology Journal 0974-6242 2018-12-25 11 4 1865 1877 10.13005/bpj/1559 24759 article Figueroa-Valverde Lauro 1 Rosas-Nexticapa Marcela 2 Mateu-Armand Virginia 2 Herrera-Meza Socorr 3 Díaz-Cedillo Francisco 4 García-Cervera Elodia 1 Laboratory of Pharmaco-Chemistry, Faculty of Chemical Biological Sciences, University, University Autonomous of Campeche, Av. Agustín Melgar s/n, Col Buenavista C.P. 24039 Campeche, Camp.,México. Facultad de Nutrición, Universidad Veracruzana, Médicos y Odontologos s/n C.P. 91010, Unidad del Bosque Xalapa Veracruz, México. Instituto de Investigaciones Psicológicas, Universidad Veracruzana. Av. Dr. Luis Castelazo Ayala s/n Col Industrial Animas. C.P. 91190, Xalapa, Veracruz, México. Escuela Nacional de Ciencias Biológicas del Instituto Politécnico Nacional. Prol. Carpio y Plan de Ayala s/n Col. Santo Tomas, México. The main objective of this study was to evaluate the biological activity of a new compound (derived from aza-bicyclo-carboxylic acid) against heart failure caused by the ischemia- reperfusion phenomenon. In addition, to characterize de molecular mechanism involved in the effect exerted by aza-bicyclo-carboxylic acid against infarction area, some drugs such as prazosin, metoprolol, propanolol, tamoxifen, flutamide, finasteride, nifedipine, levosimedan, adenosine, rolofylline, isoproterenol and the compound ZM-241385 were used as pharmacological tools.  The data found indicated that biological activity induced by compound 3 on infarction area only was similar at effect exerted by adenosine; however, the effect produced by compound 3 was blocked with of rolofylline. Other data showed that the biological activity of compound 3 decreases the cAMP levels in a time-dependent manner. In conclusion, the results indicate that compound 3 can produce a cardioprotective effect against myocardial ischemia-reperfusion injury translated as a decrease on infarction area; this phenomenon involves A₁-adenosine receptor activation and, as a result may cause changes in cAMP levels. https://biomedpharmajournal.org/vol11no4/evaluation-of-biological-activity-exerted-by-an-aza-bicyclo-carboxylic-acid-derivative-using-an-ischemia-reperfusion-injury-model/ Adenosine  Camp  Ischemia  Reperfusion  Rolofylline